By physician referral or invitation only

A phase 3 study of Nipocalimab in pregnancies at risk for severe HDFN

To evaluate the efficacy of nipocalimab compared with placebo on reducing the risk of fetal anemia with live neonates in pregnant participants at risk for severe HDFN.

Age & Gender

18 years ~ 45 years
Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Bill Goodnight
Obstetrics and Gynecology-Maternal Fetal Medicine

Study Type

Clinical or Medical
Interventional

Study Topics

Pregnancy
Rare Diseases

IRB Number

23-2842

ClinicalTrials.gov

NCT05912517

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.